Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides

Citations Over TimeTop 10% of 2012 papers

Abstract

Angiotensin-I converting enzyme (ACE), a two-domain dipeptidylcarboxypeptidase, is a key regulator of blood pressure as a result of its critical role in the renin-angiotensin-aldosterone and kallikrein-kinin systems. Hence it is an important drug target in the treatment of cardiovascular diseases. ACE is primarily known for its ability to cleave angiotensin I (Ang I) to the vasoactive octapeptide angiotensin II (Ang II), but is also able to cleave a number of other substrates including the vasodilator bradykinin and N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP), a physiological modulator of hematopoiesis. For the first time we provide a detailed biochemical and structural basis for the domain selectivity of the natural peptide inhibitors of ACE, bradykinin potentiating peptide b and Ang II. Moreover, Ang II showed selective competitive inhibition of the carboxy-terminal domain of human somatic ACE providing evidence for a regulatory role in the human renin-angiotensin system (RAS).

Related Papers

• → Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors(1998)17 cited
• → ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS AND KININ METABOLISM: EVIDENCE THAT ACE INHIBITORS MAY INHIBIT A KININASE OTHER THAN ACE(1995)33 cited
• → Increased Bradykinin Levels Accompany the Hemodynamic Response to Acute Inhibition of Angiotensin-Converting Enzyme in Dogs with Heart Failure(1999)28 cited
• → Involvement of the kallikrein‐kinin system in the antihypertensive effect of the angiotensin converting enzyme inhibitors.(1989)12 cited
• Bradykinin analogs as inhibitors of angiotensin-converting enzyme.(1994)